PCRX stock forecast
Our latest prediction for Pacira Biosciences, Inc.'s stock price was made on the Aug. 17, 2020 when the stock price was at 62.25$.
In the short term (2weeks), PCRX's stock price should underperform the market by -0.69%. During that period the price should oscillate between -6.64% and +5.19%.
In the medium term (3months), PCRX's stock price should underperform the market by -4.08%. During that period the price should oscillate between -22.50% and +13.19%.Get email alerts
Create a solid portfolio with PCRX
About Pacira Biosciences, Inc.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
At the moment the company generates 408M USD in revenues.
On its last earning announcement, the company reported a loss of -0.25$ per share.
The book value per share is 7.09$
Three months stock forecastAug. 17, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|